What is Leuprorelin Acetate?

Leuprorelin Acetate (CAS Number: 53714-56-0) is a highly potent synthetic GnRH (gonadotropin-releasing hormone) agonist. It is designed to regulate reproductive hormones by initially stimulating and then desensitizing pituitary GnRH receptors, which inhibits the release of FSH (follicle-stimulating hormone) and LH (luteinizing hormone). This results in a controlled reduction of estrogen and testosterone levels, making it essential in managing hormone-sensitive conditions.

Standard: In-House / IP / EP / BP. Leuprorelin Acetate is a key API in long-acting injectable formulations, widely used for its regulatory effect on reproductive hormones.

Applications of Leuprorelin Acetate

Leuprorelin Acetate is clinically applied across several therapeutic areas:

• 1. Oncology: Effective for hormone-sensitive prostate cancer and specific estrogen-dependent breast cancers, achieving long-term hormone suppression for better disease management.
• 2. Gynecology: Treats endometriosis by reducing pelvic pain and lesion growth, and manages uterine fibroids pre-surgery by lowering estrogen levels.
• 3. Pediatric Endocrinology: Controls central precocious puberty by regulating premature hormonal activation, supporting age-appropriate physical and hormonal development.

Key Benefits of Our Leuprorelin Acetate

• High purity suitable for regulated pharmaceutical markets
• Stable for long-acting injectable formulations
• Complies with major pharmacopeia standards (IP, EP, BP)
• Consistent batch quality ensures reliable global supply
• Supports pharmaceutical partners in developing innovative hormonal therapies

Available Dosage Forms

• Subcutaneous depot injections
• Intramuscular depot formulations

Safety & Medical Guidance

Leuprorelin Acetate should only be administered under professional medical supervision. Patients are monitored with hormone levels and clinical evaluations to ensure optimal therapeutic response and minimize potential side effects, which may include temporary hormonal fluctuations or injection site reactions.